Brief: Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency
14/04/2021 12:37
April 14 (Reuters) - Inozyme Pharma Inc INZY.O :
* INOZYME PHARMA PRESENTS DATA FROM BURDEN OF ILLNESS STUDY
IN
PATIENTS WITH ENPP1 DEFICIENCY AND ABCC6 DEFICIENCY AT THE 2021
ANNUAL CLINICAL GENETICS MEETING OF THE AMERICAN COLLEGE OF
MEDICAL GENETICS AND GENOMICS
Source text for Eikon: ID:nGNX1qXBkp
Further company coverage: INZY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inozyme Pharma
See all newsBrief: Inozyme Pharma postpones 2025 annual meeting of stockholders
U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
U.S. STOCKS ON THE MOVE-Inozyme Pharma, Emerson Electric, Stanley Black & Decker
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin